🔗 Share this article

An underground market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.

Experimental Drug Gaining Traction Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are encouraged to contact these accounts privately for source information, while also receiving discount codes.

Thriving Trade on Social Networks

Separately, a robust trade exists on messaging services, where groups with thousands of participants share comparison images, administration instructions and claims of rapid UK delivery. Vendors market the substance there before redirecting customers to WhatsApp for transactions.

Understanding Retatrutide

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and pancreatic hormone. Early trials indicate it could assist individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Concerns

However, doctors and pharmacists have cautions that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to users injecting products of unknown origin.

Some experts said the popularity for retatrutide could be connected to the increasing cost of approved slimming products such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved drug that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate medicines, advertising, and consumer regulations, risking penalties, legal action or imprisonment.

Service Response and Content Elimination

According to TikTok, the service has taken down violative content and banned associated keywords and search suggestions. The company stated it was dedicated to keeping the platform secure and investing in enhancing enforcement strategies.

Digital Trading Activities

Investigations also found communities with up to 9,000 participants selling retatrutide using the platform's integrated discovery tool, which operates like a public directory. Entering “retatrutide” immediately brings up groups with numerous of members, filled with photos of slimming results, glowing reviews and step-by-step guides for mixing or administering at residence.

After moments of joining one group, a seller posted WhatsApp details, where most purchases occur. The vendor sent an guidebook and promised shipping within 48 hours. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or past usage.

Product Information and Costs

Within these groups, posts show black plastic parcels with Royal Mail stickers, claiming to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with purified liquid, or pre-filled injectors usually priced at £160 for 20mg. When asked how much time a injector should be used, sellers give conflicting answers varying between a several days to “depends on your body”.

Service Moderation and Safety Measures

A spokesperson for Telegram said it actively monitored dangerous content on its platform including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Cautions

“Individuals are injecting substances they cannot confirm. Even if the research behind retatrutide is sound, these digital versions may not include what they claim,” stated Jason Murphy, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the increase in demand to recent cost increases for approved slimming drugs such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit injections are highly risky. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she explained.

Her staff has already encountered patients injured by self-injection from unverified sources. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your health,” stated the doctor. “These substances could be contaminated or improperly measured.”

Producer Statement

A representative from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this time no one can market [it] for human use,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental product not yet approved … may expose users to potentially significant health risks”.